N-Methylbenzylamine

We are N-Methylbenzylamine CAS:103-67-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N-Methylbenzylamine
CAS.NO:103-67-3
Synonyms:
N-BENZYLMETHYLAMINE
Benzenemethanamine, N-methyl-
omega-Methylaminotoluene
N-Mehtylbenzylamine
N-methyl-1-phenylmethanamine
N-methylbenzenemethanamine
N-Methylbenzylamin
BENZYL METHYLAMINE
N-benzyl-N-methyl-amine
ω-Methylaminotoluene
N-Methy-N-benzylamine

Molecular Formula: C8H11N
Molecular Weight:121.18000

Physical and Chemical Properties:
Density: 0.939 g / mL at 25 ° C (lit.)
Boiling point: 184-189 ° C (lit.)
Melting point: -24 ° C
Flash point: 172 ° F
Refractive index: n20 / D 1.522 (lit.)

Specification:
Appearance: Colorless transparent liquid
Purity:≥98%
Moisture Content: ≤0.2%
Impurity: ≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Fluoxetine hydrochloride CAS:59333-67-4
Intermediates of Phenylephrine hydrochloride CAS:61-76-7
Intermediates of Phenylephrine CAS:59-42-7

 N-Methylbenzylamine


Related News: With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce.Ethyl 4-bromobutyrate CAS:2969-81-5 The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.Dimethoxymethylphenylsilane CAS:3027-21-2 The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.536-38-9 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.

Related Products
Product Name
4-(Bromomethyl)-3-fluorobenzonitrile View Details
2,5-Difluoroaniline View Details
3-pyridinecarbonitrile View Details
2-bromo-4-methyl-5-nitropyridine manufacturer 2-Bromo-9,9-diphenyl-9H-fluorene manufacturer 7-Methoxy-1-tetralone manufacturer 10-Bromo-1-decanol acetate manufacturer Ethyl 4-dimethylaminobenzoate manufacturer